Investment area
Planetary Health Investments
Region
Europe
Date of investment
September 2023
With annual revenues of greater than $100 million, Paratek is one of the largest independent antibiotics companies in the world. Its lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is the first-choice antibiotic for patients with comorbidities or suspected resistant pathogens. Paratek’s specialty pharmaceutical platform enables both the development and commercialisation of new drugs to bring new innovative therapies to patients.
Contact
Aleks Engel
Partner
Department: Planetary Health Investments
Aleks joined Novo Holdings A/S in 2014 and is Partner in the Planetary Health Investments team.
Aleks also leads Novo Holdings’ REPAIR Impact Fund targeting antimicrobial resistance.
Prior to joining Novo Holdings, Aleks was employed as VP in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, Thomson Scientific & Healthcare and McKinsey & Company (all U.S.A.).
Aleks holds a PhD in Biochemical Engineering and a MSc in Chemical Engineering Practice from Massachusetts Institute of Technology.
